FDA Approves Higher-Dose Semaglutide Under Accelerated Review Program

The FDA has approved semaglutide injection 7.2 mg (Wegovy HD; Novo Nordisk) to reduce excess body weight and maintain long-term weight reduction in adults with obesity or overweight with at least 1 weight-related condition, according to news releases from Novo Nordisk and the FDA.^1,2

The approval marks the first glucagon-like peptide-1 (GLP-1) receptor agonist approved under the Commissioner's National Priority Voucher (CNPV) program. The approval was granted just 54 days after filing, compared with the standard 10- to 12-month review timeline. Semaglutide 7.2 mg demonstrated 20.7% mean weight loss in adults with obesity in the phase 3 STEP UP trial (NCT05646706).^1-3

STEP UP Trial Results

The 72-week STEP UP trial randomly assigned 1407 adults with obesity (body mass index [BMI] of 30 or higher) without diabetes to once-weekly subcutaneous semaglutide 7.2 mg, 2.4 mg, or placebo in a 5:1:1 ratio. Participants had a mean age of 47 years, a mean body weight of 113.0 kg, and a mean BMI of 39.9. The trial evaluated the superiority of semaglutide 7.2 mg vs both 2.4 mg and placebo when used as an adjunct to lifestyle intervention.^1,3

The mean change in body weight from baseline to week 72 was significantly greater with semaglutide 7.2 mg vs 2.4 mg (–18.7% vs –15.6%; estimated treatment difference [ETD] –3.1%; 95% CI, –4.7% to –1.6%; P < .0001). Semaglutide 7.2 mg was also superior to placebo (–18.7% vs –3.9%; ETD –14.8%; 95% CI, –16.2% to –13.4%; P < .0001). Approximately one-third of participants receiving semaglutide 7.2 mg achieved 25% or greater weight loss, with a 2.4-fold higher likelihood of reaching this threshold compared with the 2.4-mg dose (95% CI, 1.6-3.5).³

In the companion STEP UP type 2 diabetes (T2D) trial of approximately 500 adults with obesity and T2D, semaglutide 7.2 mg demonstrated mean weight loss of 14.1%. The higher dose offered similar reductions in hemoglobin A_1C compared with the lower dose, while producing greater weight loss in this population, which typically has greater difficulty losing weight.^1,2

Safety Profile and Adverse Events

The safety profile of semaglutide 7.2 mg was consistent with previously approved doses. Gastrointestinal adverse events were more common with semaglutide 7.2 mg (70.8%) vs 2.4 mg (61.2%) or placebo (42.8%), including nausea, vomiting, diarrhea, constipation, and abdominal pain. Dysesthesia—altered skin sensation described as sensitivity, pain, or burning—occurred more frequently at the higher dose (22.9%) vs 2.4 mg (6.0%) or the placebo (0.5%). These symptoms generally resolved spontaneously or with dose reduction. The FDA is currently conducting further investigations regarding this adverse reaction, according to their news release. Serious adverse events occurred in 6.8% of participants receiving semaglutide 7.2 mg.^1,3

CNPV Program

The CNPV pilot program, which launched in June 2025, seeks to expedite approval of applications that address critical national health priorities, including bringing innovative therapies to patients, addressing unmet medical needs, promoting domestic manufacturing, and increasing affordability. Companies selected for the program receive enhanced communications and rolling review to allow for shortened review times of 1 to 2 months.^1,4,5

Wegovy HD joins 14 other therapies that have received CNPV designation across oncology, rare diseases, infectious diseases, and metabolic conditions. Both Novo Nordisk's Wegovy and Eli Lilly's investigational oral GLP-1, orforglipron, received vouchers tied to explicit pricing commitments for Medicare and Medicaid. The program has generated discussion within the pharmaceutical industry regarding the balance between accelerated timelines and traditional FDA review processes.^4-6

"The new FDA is moving with unprecedented efficiency on products that advance national priorities," FDA Commissioner Martin Makary, MD, MPH, said in the news release. "Today's approval is another demonstration of what the FDA can accomplish when we try bold new things."¹

Implications for Pharmacists

Semaglutide 7.2 mg is indicated for adults with obesity who have tolerated the 2.4-mg dose for at least 4 weeks and for whom additional weight reduction is clinically indicated. Pharmacists should educate patients that the higher dose provides incremental weight loss benefits but is not appropriate as initial therapy. Patients must demonstrate tolerability at 2.4 mg before escalation to 7.2 mg.¹

The increased incidence of dysesthesia with semaglutide 7.2 mg warrants specific counseling. Pharmacists should inform patients about the potential for altered skin sensation, including sensitivity, pain, or burning. While these symptoms typically resolve on their own or with dose reduction, patients experiencing concerning or persistent symptoms should contact their prescriber. The FDA's ongoing investigation into this adverse reaction may yield additional guidance.^1,2

Gastrointestinal adverse events remain the most common adverse effects across all semaglutide doses. Pharmacists should reinforce strategies to minimize these effects, including taking the medication with or without food, staying well-hydrated, consuming smaller, more frequent meals, and avoiding high-fat foods. Patients should be counseled that gastrointestinal symptoms often improve with continued use.

Novo Nordisk expects to launch semaglutide 7.2 mg in a single-dose pen in the United States in April 2026. The product will be available through the same channels as existing semaglutide formulations, including retail pharmacies, select telehealth providers, and specialty pharmacy services.²

REFERENCES

1. FDA approves fourth product under national priority voucher program, higher dose semaglutide. News release. FDA. March 19, 2026. Accessed March 19, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide

2. Novo Nordisk A/S: Wegovy HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss. News release. Novo Nordisk. March 19, 2026. Accessed March 19, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916516

3. Wharton S, Freitas P, Hjelmesæth J, et al; STEP UP trial group. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. doi:10.1016/S2213-8587(25)00226-8

4. Halpern L. FDA grants national priority vouchers to enlicitide decanoate, sacituzumab tirumotecan. Pharmacy Times. January 7, 2026. Updated January 13, 2026. Accessed March 19, 2026. https://www.pharmacytimes.com/view/fda-grants-national-priority-vouchers-to-enlicitide-decanoate-sacituzumab-tirumotecan

5. Vinluan F. FDA adds 6 more meds to pilot program for speedy review of drugs in the national interest. MedCity News. November 7, 2025. Accessed March 19, 2026. https://medcitynews.com/2025/11/fda-national-priority-review-voucher-cnpv-obesity-cancer-gene-theapy-infectious-disease/

6. Perrone M. FDA's new expedited drug program raises legal questions and concerns. PBS News. January 18, 2026. Accessed March 19, 2026. https://www.pbs.org/newshour/health/fdas-new-expedited-drug-program-raises-legal-questions-and-concerns